Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
5 studies found for:    15800326 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Conditions: Pancreatic Cancer;   Renal Cell Cancer;   Breast Cancer;   Melanoma;   Ovarian Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Anti-hCD70 CAR PBL
2 Terminated
Has Results
Drosophila-generated CTL
Condition: Metastatic Cutaneous Melanoma
Interventions: Drug: fludarabine;   Drug: cyclophosphamide;   Drug: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL;   Drug: Aldesleukin
3 Terminated Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
Condition: Metastatic Cancer
Interventions: Biological: PG13-CEA_TCR (Anti-CEA TCR PBL);   Drug: Aldesleukin
4 Not yet recruiting A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Conditions: Breast Cancer;   Chest Wall Disease
Interventions: Drug: Carboplatin, Pembrolizumab;   Drug: Carboplatin
5 Recruiting Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Condition: Acute Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Melphalan;   Drug: Pembrolizumab

Study has passed its completion date and status has not been verified in more than two years.